What Citranatal 90 Dha Treats: Main Uses and Benefits

This specialized prenatal supplement is commonly used before, during, and after pregnancy to help manage symptoms related to systemic imbalance in conditions marked by increased physiological stress. This supplement is designed to support both maternal and fetal health. Citranatal 90 Dha is used to address conditions involving specific nutritional deficiencies, playing a role in managing the risk of iron deficiency anemia and mitigating the risk of fetal structural anomalies. It offers targeted support for neurodevelopment and visual function in the developing baby through Docosahexaenoic Acid (DHA), and assists with easing gastrointestinal discomfort associated with iron intake. This comprehensive approach provides support that helps ease the overall symptom burden, which may assist with maintaining functional stability.

“The supplement is considered relevant for helping with symptoms that may interfere with daily comfort and supports patients during episodes of heightened discomfort.”

Quick Fact: Primary Therapeutic Benefits
Targeted Deficiency	Iron deficiency; Folic Acid deficiency
Fetal Focus	Support for neurodevelopment and visual function
Symptom Relief	Constipation associated with iron intake
Context of Use	Throughout the entire perinatal cycle

Regulatory References

1. NIH MedlinePlus information on prenatal vitamins

Eligibility Map: Who can and cannot use Citranatal 90 Dha

This map details the populations defined as eligible or restricted for use according to official regulatory labeling.

---

Eligibility Scope

The supplement is indicated for use by women prior to conception, throughout pregnancy, and during the postnatal period, including lactating mothers. The regulatory scope establishes this specific female population as the group for whom the product is intended.

Populations for whom use is contraindicated:

• Patients with a known hypersensitivity to any ingredient in the product.

Populations for whom use is not recommended:

• Patients with pernicious anemia or other B12-deficiency megaloblastic anemias, as the folic acid component is considered improper therapy.
• Patients taking anticoagulants or those with a bleeding diathesis; the DHA softgel component should be avoided in these instances.

Age-related eligibility rules:

The product must be kept out of the reach of children under six years old, as accidental iron-containing product overdose is a primary cause of fatal poisoning in this age group.

Connection to the overall eligibility profile:

Official labeling establishes a defined target population while simultaneously setting strict prohibitions based on hypersensitivity and specific comorbidity risks related to both the folic acid (hematological caution) and DHA (coagulation risk) components.

Interactions with other medicines and products

Official regulatory information describes interactions for Citranatal 90 Dha primarily based on its mineral and fatty acid components.

Pharmacokinetic and Pharmacodynamic Interactions

Classification	Interacting Agents or Conditions	Official Statement
Pharmacokinetic	Antibiotics (Quinolones, Tetracyclines), Thyroid Medications (Levothyroxine), Bisphosphonates	The Iron and Calcium components may cause a decreased absorption and reduced systemic exposure of co-administered agents via chelation.
Pharmacodynamic	Anticoagulants (e.g., Warfarin)	The Docosahexaenoic Acid (DHA) component carries the risk of increased bleeding time and INR (International Normalized Ratio) and should be avoided in this context.

---

Administration and Condition-Specific Restrictions

Administration requires timing separation to manage absorption-based interactions. Antacids and Dairy Products should not be taken within two hours of the supplement to maintain effectiveness. Doses of chelation-susceptible drugs should be separated as far as possible.

Additionally, the Folic Acid content introduces a condition-specific restriction: Folic Acid alone is designated as improper therapy in patients with underlying Vitamin B12 deficiency because it can obscure the diagnosis of pernicious anemia while neurological deterioration progresses. Similarly, the supplement is avoided in patients with a pre-existing bleeding diathesis due to the Omega-3 component.

Cofactor Role in Enhanced Metabolic Pathways

This domain encompasses the function of B vitamins and Iron, which serve as cofactors and substrates essential for ATP generation, nucleotide synthesis, and erythropoiesis. This activity results in the maintenance of cellular function necessary to meet increased demands for oxygen delivery and molecular building blocks.

Incorporation into Neural and Retinal Membrane Lipids

This block addresses the structural and functional role of Docosahexaenoic Acid (DHA), a long-chain omega-3 fatty acid. DHA is actively transported across the placenta and incorporated as a fundamental component of cell membranes, particularly concentrated in the retina and central nervous system, influencing the biophysical properties of cell membranes critical for synaptic function and phototransduction.

Regulation of Endocrine and Transport Systems

This cluster involves essential minerals like Calcium and Magnesium, and vitamins such as Vitamin D and Iodine. These components regulate specific transmembrane transport processes and transcription factors that govern bone mineralization and thyroid hormone synthesis. This mechanism ensures the correct titration of signaling pathways vital for skeletal and nervous system maturation.

Citranatal 90 Dha is an oral combination regimen prescribed for daily use throughout the perinatal period. The usage pattern involves ingesting two distinct components as one daily unit: the multivitamin/mineral tablet and the separate DHA softgel. This standardized dosage unit is intended for long-term use, commencing in the preconception phase, continuing throughout pregnancy, and extending into the postnatal period for both lactating and non-lactating mothers. The tablet component contains fixed concentrations of essential nutrients, including 1 mg of Folic Acid and 90 mg of elemental iron.

Administration Conditions and Constraints

The dosage unit is to be swallowed whole once daily with water. Standard administration involves taking the dose on an empty stomach for optimal absorption, though taking it with food is permissible to mitigate potential stomach discomfort. Furthermore, administration is governed by specific procedural constraints to maximize efficacy and tolerance. For instance, the protocol includes not lying down for at least 10 minutes after ingestion. To prevent interference with the absorption of essential minerals, specific consumables like antacids, dairy products, tea, or coffee must be avoided within two hours before or after taking the dose. These guidelines establish a structured daily protocol that defines the full course of use across the entire reproductive cycle.

Administration Scope	Official Guideline
Route of administration	Oral (tablet and softgel)
Dosing schedule	One tablet and one softgel, once daily
Use-context constraints	Avoid dairy, antacids, tea, or coffee within two hours of the dose

The research base for Citranatal 90 Dha is derived from established scientific literature supporting its essential components (Folic Acid, Iron, DHA) during the perinatal period. These authoritative sources describe how the components were studied for monitoring maternal nutrient status and exploring outcomes related to fetal development.

---

Evidence on Core Nutritional Status and Deficiency Prevention

Large observational studies and systematic reviews examined outcomes related to maternal blood levels of key nutrients, such as iron and folate. Findings indicate that comprehensive multivitamin-mineral supplementation was evaluated in relation to established Recommended Daily Allowances (RDAs). However, specific data for this combination product are often embedded within the broader evidence base for general prenatal multivitamin use, limiting the ability to isolate its effect.

---

Research on Folic Acid and Fetal Structural Outcomes

Folic acid was evaluated in women in the periconceptional period, with Randomized Controlled Trials (RCTs) and case-control studies examining the incidence of Neural Tube Defects (NTDs), such as spina bifida. Findings indicate that the Folic Acid component was associated with patterns related to the incidence of NTDs when used during the critical early developmental window. The research base includes documented RCTs, and the evidence for Folic Acid in this context is generally described as High-level.

---

Studies on DHA and Developmental Endpoints

The Docosahexaenoic Acid (DHA) component was studied for its role in fetal brain and retina development. Researchers monitored high-level neurodevelopmental endpoints and visual outcomes in infants following maternal supplementation. Findings were mixed regarding patterns related to global cognitive scores in children born to mothers in the general population. While some RCTs described patterns related to visual acuity, overall certainty remains low regarding a broad impact on long-term global outcomes.

---

Research Gaps and Limitations

The overall evidence quality varies across studies. Comparative evidence is lacking to definitively show the unique benefits of this specific formulation over other available prenatal supplements. Furthermore, long-term effects for the offspring of supplemented mothers are not fully established beyond early childhood, and subgroup findings regarding who may benefit most remain uncertain.

Key Studies & References

1. RCOG Scientific Impact Paper No. 43: Healthy eating and vitamin supplements in pregnancy
2. Could early life DHA supplementation benefit neurodevelopment? A systematic review and meta-analysis - Frontiers

Common questions about Citranatal 90 Dha (FAQ)

---

Q: Can Citranatal 90 Dha cause stomach upset or nausea?

Regulatory documents state that documented adverse reactions for components of the supplement include gastrointestinal distress. This may encompass symptoms such as nausea or stomach upset.

Patients experiencing persistent discomfort should consult with their healthcare provider for guidance.

---

Q: What is meant by the term 'dietary supplement' when referring to Citranatal 90 Dha?

Official FDA and DailyMed documents classify Citranatal 90 Dha as a prescription-only combination drug product. While it contains vitamins and minerals, which function as nutritional supplements, its regulatory status is that of a specialized prescription drug product.

---

Q: Is it true that the iron in prenatal vitamins like Citranatal 90 Dha can contribute to constipation?

The iron component of prenatal vitamins can commonly contribute to constipation. The official formulation of Citranatal 90 Dha specifically addresses this concern by including Docusate Sodium, which functions as a stool softener.

---

Q: Does Citranatal 90 Dha contain any known allergens like soy or fish?

Official labeling confirms that the Docosahexaenoic Acid (DHA) softgel component is typically derived from a fish oil source. The product is contraindicated for individuals with a known hypersensitivity to any ingredient, which includes the fish oil-derived component.

---

Q: Can people who are not pregnant take Citranatal 90 Dha?

The product is indicated for use by women who are planning conception, are pregnant, or are in the postnatal period, including those who are breastfeeding. Use outside of this specific, indicated population is not generally addressed in regulatory documents.

---

Q: Does the formulation of Citranatal 90 Dha meet the official guidelines for key prenatal nutrients?

Official product labeling indicates that the formulation's components and dosages are calibrated to align with or exceed the established U.S. Recommended Daily Allowances (RDAs) for key nutrients required by pregnant and lactating women.

---

Q: Is it possible to take excessive amounts of the vitamins in Citranatal 90 Dha?

Official warnings state that overdose, particularly due to the high iron content, is a serious risk. Accidental overdose of iron-containing products can be fatal in children under six years old and may cause serious complications in adults.

---

Q: How is the iron in Citranatal 90 Dha absorbed by the body?

The iron component, which is provided as Ferrous Gluconate, is absorbed in the gastrointestinal tract using the body's natural processes for mineral uptake.

---

Q: Is it necessary to take Citranatal 90 Dha if a person is eating a very balanced diet?

Official sources describe the product's purpose as meeting the increased physiological demands of pregnancy. The formulation is intended to ensure consistent nutrient levels that a typical balanced diet may not fully satisfy during this critical period.

---

Q: Can the physical pill of Citranatal 90 Dha be cut in half or crushed to make it easier to swallow?

According to the official administration information, the dosage unit is instructed to be swallowed whole once daily. Regulatory documents do not provide authorization for cutting, crushing, or otherwise altering the physical form of the tablet or softgel.

---

Q: What is the officially suggested duration for taking Citranatal 90 Dha after delivery?

The usage regimen is specified for the postnatal period, which includes the duration of breastfeeding. Official labeling does not mandate a specific duration, as continued use is typically determined by a healthcare provider's assessment of individual nutritional needs.

---

Q: Are there known situations where the use of Citranatal 90 Dha might be stopped or paused?

Regulatory documents require that use must be stopped immediately if a severe adverse reaction or a hypersensitivity (allergic reaction) is suspected. The product is also contraindicated and should be avoided in patients with certain pre-existing conditions, such as a known bleeding diathesis.

---

Q: Can the components of Citranatal 90 Dha be separated into multiple capsules throughout the day?

The prescribed regimen is for the entire daily unit—one tablet and one softgel—to be taken once daily. Regulatory information does not support or authorize splitting the daily dose unit into separate administrations staggered throughout the day.

---

Q: What is the general safety classification of Citranatal 90 Dha for use during pregnancy, as described by regulatory bodies?

Official labeling confirms this product is a prescription-only prenatal supplement specifically intended for nutritional support during pregnancy. Regulatory agencies now provide detailed risk summaries in product labeling rather than a simple letter category to describe safety information during this period.

---

Q: What is the source of the DHA in Citranatal 90 Dha?

According to the official ingredients list, the Docosahexaenoic Acid (DHA) component is derived from refined fish oil.

---

Q: Is it normal for the color of urine to change after starting Citranatal 90 Dha?

Yes, the Riboflavin component, also known as Vitamin B2, is known to cause a harmless yellow-to-orange discoloration of the urine. This is a common, expected effect of taking multivitamins containing Riboflavin.

---

Q: Is there a different form of folic acid in Citranatal 90 Dha compared to other supplements?

The official ingredients list specifies the component as Folic Acid (pteroylglutamic acid). This is the standard synthetic form of the vitamin that is commonly found in most multivitamin and prenatal supplements.

---

Q: Does Citranatal 90 Dha contain Vitamin A, and if so, what are the official warnings about the amount?

Official product labeling indicates that Vitamin A is not listed as an active ingredient in this specific formulation of Citranatal 90 Dha.

---

Q: What are the steps to take if an allergic reaction is suspected after using Citranatal 90 Dha?

Allergic sensitization has been documented with ingredients like Folic Acid. Official safety documentation indicates that if any suspected severe allergic symptoms occur, seeking prompt medical attention is the general safety protocol.

---

Q: Is Citranatal 90 Dha suitable for individuals who follow a vegetarian or vegan diet?

Because the Docosahexaenoic Acid (DHA) component is derived from fish oil, the product is not suitable for individuals who adhere to a vegetarian or vegan diet.

---

Q: Can taking Citranatal 90 Dha cause dark-colored stools?

Yes, the iron content in the supplement is known to cause dark, black, or tarry stools. This is described as a common, non-serious side effect of iron supplementation.

---

Q: Why is Choline sometimes included in prenatal vitamins, and is it a component of Citranatal 90 Dha?

Choline is a nutrient sometimes included in prenatal vitamins, but the official ingredients list confirms that Choline is not a listed component of the Citranatal 90 Dha formulation.

How to Store and Dispose of CitraNatal 90 DHA

Official labeling mandates specific conditions for the storage and handling of CitraNatal 90 DHA, primarily to maintain product stability and ensure child safety.

Storage Requirements

Condition	Requirement
Temperature	Must be stored at controlled room temperature, 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted up to 30 C (86 F).
Protection	Protection from moisture is necessary, as contact with moisture can discolor or erode the tablet component.
Child Safety	KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. This is a mandatory warning due to the risk of accidental fatal poisoning from iron in children under six.

Disposal

Unused or expired CitraNatal 90 DHA must be discarded after the expiration date and disposed of according to local medication disposal guidelines. The product should not be flushed down a toilet or poured into a drain unless specifically advised by official sources.